APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-invasive Insulin

Compare research editions
View pricing & licenses

Selected research

Industry Research

Non-invasive Insulin Industry Research Report 2026

27 December 2025126 pages

Choose your research edition.

Industry ResearchNon-invasive Insulin Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-invasive Insulin Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Non-invasive Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-invasive Insulin Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-invasive Insulin Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Non-invasive Insulin market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Non-invasive Insulin is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Non-invasive Insulin is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Non-invasive Insulin is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Non-invasive Insulin include Sanofi, Novo Nordisk, Eli Lilly, Biocon, Zafgen, Verily Life Sciences, Senseonics, Oramed Pharmaceuticals and Medtronic, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Non-invasive Insulin market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Non-invasive Insulin Market by Company

Sanofi

Novo Nordisk

Eli Lilly

Biocon

Zafgen

Verily Life Sciences

Senseonics

Oramed Pharmaceuticals

Medtronic

MannKind Corporation

Janssen Pharmaceuticals

Dance Biopharm

Bigfoot Biomedical

Adocia

Non-invasive Insulin Segment by Type

Pills

Sprays

Others

Non-invasive Insulin Segment by Application

Hospital Pharmacies

Online Pharmacies

Drug Stores

Non-invasive Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-invasive Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-invasive Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-invasive Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Non-invasive Insulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Non-invasive Insulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Non-invasive Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Non-invasive Insulin Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Non-invasive Insulin Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Non-invasive Insulin Sales Market Share by Manufacturers (2021-2026) Table 8. Global Non-invasive Insulin Revenue of Manufacturers (2021-2026) Table 9. Global Non-invasive Insulin Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Non-invasive Insulin Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Non-invasive Insulin Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Non-invasive Insulin, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Non-invasive Insulin, Product Type & Application Table 14. Global Non-invasive Insulin Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Non-invasive Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sanofi Non-invasive Insulin Product Portfolio Table 22. Sanofi Recent Developments Table 23. Novo Nordisk Company Information Table 24. Novo Nordisk Business Overview Table 25. Novo Nordisk Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Novo Nordisk Non-invasive Insulin Product Portfolio Table 27. Novo Nordisk Recent Developments Table 28. Eli Lilly Company Information Table 29. Eli Lilly Business Overview Table 30. Eli Lilly Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Eli Lilly Non-invasive Insulin Product Portfolio Table 32. Eli Lilly Recent Developments Table 33. Biocon Company Information Table 34. Biocon Business Overview Table 35. Biocon Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Biocon Non-invasive Insulin Product Portfolio Table 37. Biocon Recent Developments Table 38. Zafgen Company Information Table 39. Zafgen Business Overview Table 40. Zafgen Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Zafgen Non-invasive Insulin Product Portfolio Table 42. Zafgen Recent Developments Table 43. Verily Life Sciences Company Information Table 44. Verily Life Sciences Business Overview Table 45. Verily Life Sciences Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Verily Life Sciences Non-invasive Insulin Product Portfolio Table 47. Verily Life Sciences Recent Developments Table 48. Senseonics Company Information Table 49. Senseonics Business Overview Table 50. Senseonics Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Senseonics Non-invasive Insulin Product Portfolio Table 52. Senseonics Recent Developments Table 53. Oramed Pharmaceuticals Company Information Table 54. Oramed Pharmaceuticals Business Overview Table 55. Oramed Pharmaceuticals Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Oramed Pharmaceuticals Non-invasive Insulin Product Portfolio Table 57. Oramed Pharmaceuticals Recent Developments Table 58. Medtronic Company Information Table 59. Medtronic Business Overview Table 60. Medtronic Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Medtronic Non-invasive Insulin Product Portfolio Table 62. Medtronic Recent Developments Table 63. MannKind Corporation Company Information Table 64. MannKind Corporation Business Overview Table 65. MannKind Corporation Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. MannKind Corporation Non-invasive Insulin Product Portfolio Table 67. MannKind Corporation Recent Developments Table 68. Janssen Pharmaceuticals Company Information Table 69. Janssen Pharmaceuticals Business Overview Table 70. Janssen Pharmaceuticals Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Janssen Pharmaceuticals Non-invasive Insulin Product Portfolio Table 72. Janssen Pharmaceuticals Recent Developments Table 73. Dance Biopharm Company Information Table 74. Dance Biopharm Business Overview Table 75. Dance Biopharm Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Dance Biopharm Non-invasive Insulin Product Portfolio Table 77. Dance Biopharm Recent Developments Table 78. Bigfoot Biomedical Company Information Table 79. Bigfoot Biomedical Business Overview Table 80. Bigfoot Biomedical Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Bigfoot Biomedical Non-invasive Insulin Product Portfolio Table 82. Bigfoot Biomedical Recent Developments Table 83. Adocia Company Information Table 84. Adocia Business Overview Table 85. Adocia Non-invasive Insulin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Adocia Non-invasive Insulin Product Portfolio Table 87. Adocia Recent Developments Table 88. Global Non-invasive Insulin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 89. Global Non-invasive Insulin Sales by Region (2021-2026) & (K Units) Table 90. Global Non-invasive Insulin Sales Market Share by Region (2021-2026) Table 91. Global Non-invasive Insulin Sales by Region (2027-2032) & (K Units) Table 92. Global Non-invasive Insulin Sales Market Share by Region (2027-2032) Table 93. Global Non-invasive Insulin Revenue by Region (2021-2026) & (US$ Million) Table 94. Global Non-invasive Insulin Revenue Market Share by Region (2021-2026) Table 95. Global Non-invasive Insulin Revenue by Region (2027-2032) & (US$ Million) Table 96. Global Non-invasive Insulin Revenue Market Share by Region (2027-2032) Table 97. North America Non-invasive Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. North America Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 99. North America Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 100. North America Non-invasive Insulin Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Non-invasive Insulin Revenue by Country (2027-2032) & (US$ Million) Table 102. Europe Non-invasive Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. Europe Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 104. Europe Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 105. Europe Non-invasive Insulin Revenue by Country (2021-2026) & (US$ Million) Table 106. Europe Non-invasive Insulin Revenue by Country (2027-2032) & (US$ Million) Table 107. Asia Pacific Non-invasive Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Asia Pacific Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 109. Asia Pacific Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 110. Asia Pacific Non-invasive Insulin Revenue by Country (2021-2026) & (US$ Million) Table 111. Asia Pacific Non-invasive Insulin Revenue by Country (2027-2032) & (US$ Million) Table 112. South America Non-invasive Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. South America Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 114. South America Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 115. South America Non-invasive Insulin Revenue by Country (2021-2026) & (US$ Million) Table 116. South America Non-invasive Insulin Revenue by Country (2027-2032) & (US$ Million) Table 117. Middle East and Africa Non-invasive Insulin Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Middle East and Africa Non-invasive Insulin Sales by Country (2021-2026) & (K Units) Table 119. Middle East and Africa Non-invasive Insulin Sales by Country (2027-2032) & (K Units) Table 120. Middle East and Africa Non-invasive Insulin Revenue by Country (2021-2026) & (US$ Million) Table 121. Middle East and Africa Non-invasive Insulin Revenue by Country (2027-2032) & (US$ Million) Table 122. Global Non-invasive Insulin Sales by Type (2021-2026) & (K Units) Table 123. Global Non-invasive Insulin Sales by Type (2027-2032) & (K Units) Table 124. Global Non-invasive Insulin Sales Market Share by Type (2021-2026) Table 125. Global Non-invasive Insulin Sales Market Share by Type (2027-2032) Table 126. Global Non-invasive Insulin Revenue by Type (2021-2026) & (US$ Million) Table 127. Global Non-invasive Insulin Revenue by Type (2027-2032) & (US$ Million) Table 128. Global Non-invasive Insulin Revenue Market Share by Type (2021-2026) Table 129. Global Non-invasive Insulin Revenue Market Share by Type (2027-2032) Table 130. Global Non-invasive Insulin Price by Type (2021-2026) & (US$/Unit) Table 131. Global Non-invasive Insulin Price by Type (2027-2032) & (US$/Unit) Table 132. Global Non-invasive Insulin Sales by Application (2021-2026) & (K Units) Table 133. Global Non-invasive Insulin Sales by Application (2027-2032) & (K Units) Table 134. Global Non-invasive Insulin Sales Market Share by Application (2021-2026) Table 135. Global Non-invasive Insulin Sales Market Share by Application (2027-2032) Table 136. Global Non-invasive Insulin Revenue by Application (2021-2026) & (US$ Million) Table 137. Global Non-invasive Insulin Revenue by Application (2027-2032) & (US$ Million) Table 138. Global Non-invasive Insulin Revenue Market Share by Application (2021-2026) Table 139. Global Non-invasive Insulin Revenue Market Share by Application (2027-2032) Table 140. Global Non-invasive Insulin Price by Application (2021-2026) & (US$/Unit) Table 141. Global Non-invasive Insulin Price by Application (2027-2032) & (US$/Unit) Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Non-invasive Insulin Distributors List Table 145. Non-invasive Insulin Customers List Table 146. Non-invasive Insulin Industry Trends Table 147. Non-invasive Insulin Industry Drivers Table 148. Non-invasive Insulin Industry Restraints Table 149. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Non-invasive Insulin Product Image Figure 5. Global Non-invasive Insulin Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Non-invasive Insulin Market Size (2021-2032) & (US$ Million) Figure 7. Global Non-invasive Insulin Sales (2021-2032) & (K Units) Figure 8. Global Non-invasive Insulin Average Price (US$/Unit) & (2021-2032) Figure 9. Pills Product Image Figure 10. Sprays Product Image Figure 11. Others Product Image Figure 12. Hospital Pharmacies Product Image Figure 13. Online Pharmacies Product Image Figure 14. Drug Stores Product Image Figure 15. Global Non-invasive Insulin Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Non-invasive Insulin, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Non-invasive Insulin Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Non-invasive Insulin Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Non-invasive Insulin Sales by Region in 2025 Figure 21. Global Non-invasive Insulin Revenue by Region in 2025 Figure 22. North America Non-invasive Insulin Market Size by Country in 2025 Figure 23. North America Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 24. North America Non-invasive Insulin Revenue Market Share by Country (2021-2032) Figure 25. United States Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Non-invasive Insulin Market Size by Country in 2025 Figure 29. Europe Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 30. Europe Non-invasive Insulin Revenue Market Share by Country (2021-2032) Figure 31. Germany Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Non-invasive Insulin Market Size by Country in 2025 Figure 42. Asia Pacific Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Non-invasive Insulin Revenue Market Share by Country (2021-2032) Figure 44. China Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Non-invasive Insulin Market Size by Country in 2025 Figure 53. South America Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 54. South America Non-invasive Insulin Revenue Market Share by Country (2021-2032) Figure 55. Brazil Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Non-invasive Insulin Market Size by Country in 2025 Figure 59. Middle East and Africa Non-invasive Insulin Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Non-invasive Insulin Revenue Market Share by Country (2021-2032) Figure 61. Egypt Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Non-invasive Insulin Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Non-invasive Insulin Sales Market Share by Type (2021-2032) Figure 67. Global Non-invasive Insulin Revenue Market Share by Type (2021-2032) Figure 68. Global Non-invasive Insulin Price (US$/Unit) by Type (2021-2032) Figure 69. Global Non-invasive Insulin Sales Market Share by Application (2021-2032) Figure 70. Global Non-invasive Insulin Revenue Market Share by Application (2021-2032) Figure 71. Global Non-invasive Insulin Price (US$/Unit) by Application (2021-2032) Figure 72. Non-invasive Insulin Value Chain Figure 73. Non-invasive Insulin Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Non-invasive Insulin Industry Opportunities and Challenges

Scope & coverage.

Types
  • Pills
  • Sprays
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Drug Stores
Companies covered
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • Biocon
  • Zafgen
  • Verily Life Sciences
  • Senseonics
  • Oramed Pharmaceuticals
  • Medtronic
  • MannKind Corporation
  • Janssen Pharmaceuticals
  • Dance Biopharm
  • Bigfoot Biomedical
  • Adocia

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Non-invasive Insulin Market Size (2021-2032)
  4. 2.2.2 Global Non-invasive Insulin Sales (2021-2032)
  5. 2.2.3 Global Non-invasive Insulin Market Average Price (2021-2032)
  6. 2.3 Non-invasive Insulin by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Pills
  9. 2.3.3 Sprays
  10. 2.3.4 Others
  11. 2.4 Non-invasive Insulin by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital Pharmacies
  14. 2.4.3 Online Pharmacies
  15. 2.4.4 Drug Stores
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Non-invasive Insulin Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Non-invasive Insulin Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Non-invasive Insulin Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Non-invasive Insulin Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Non-invasive Insulin Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Non-invasive Insulin, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Non-invasive Insulin, Product Type & Application
  8. 3.8 Global Manufacturers of Non-invasive Insulin, Established Date
  9. 3.9 Global Non-invasive Insulin Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi Non-invasive Insulin Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 Novo Nordisk
  8. 4.2.1 Novo Nordisk Company Information
  9. 4.2.2 Novo Nordisk Business Overview
  10. 4.2.3 Novo Nordisk Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Novo Nordisk Non-invasive Insulin Product Portfolio
  12. 4.2.5 Novo Nordisk Recent Developments
  13. 4.3 Eli Lilly
  14. 4.3.1 Eli Lilly Company Information
  15. 4.3.2 Eli Lilly Business Overview
  16. 4.3.3 Eli Lilly Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Eli Lilly Non-invasive Insulin Product Portfolio
  18. 4.3.5 Eli Lilly Recent Developments
  19. 4.4 Biocon
  20. 4.4.1 Biocon Company Information
  21. 4.4.2 Biocon Business Overview
  22. 4.4.3 Biocon Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Biocon Non-invasive Insulin Product Portfolio
  24. 4.4.5 Biocon Recent Developments
  25. 4.5 Zafgen
  26. 4.5.1 Zafgen Company Information
  27. 4.5.2 Zafgen Business Overview
  28. 4.5.3 Zafgen Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Zafgen Non-invasive Insulin Product Portfolio
  30. 4.5.5 Zafgen Recent Developments
  31. 4.6 Verily Life Sciences
  32. 4.6.1 Verily Life Sciences Company Information
  33. 4.6.2 Verily Life Sciences Business Overview
  34. 4.6.3 Verily Life Sciences Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Verily Life Sciences Non-invasive Insulin Product Portfolio
  36. 4.6.5 Verily Life Sciences Recent Developments
  37. 4.7 Senseonics
  38. 4.7.1 Senseonics Company Information
  39. 4.7.2 Senseonics Business Overview
  40. 4.7.3 Senseonics Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Senseonics Non-invasive Insulin Product Portfolio
  42. 4.7.5 Senseonics Recent Developments
  43. 4.8 Oramed Pharmaceuticals
  44. 4.8.1 Oramed Pharmaceuticals Company Information
  45. 4.8.2 Oramed Pharmaceuticals Business Overview
  46. 4.8.3 Oramed Pharmaceuticals Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Oramed Pharmaceuticals Non-invasive Insulin Product Portfolio
  48. 4.8.5 Oramed Pharmaceuticals Recent Developments
  49. 4.9 Medtronic
  50. 4.9.1 Medtronic Company Information
  51. 4.9.2 Medtronic Business Overview
  52. 4.9.3 Medtronic Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Medtronic Non-invasive Insulin Product Portfolio
  54. 4.9.5 Medtronic Recent Developments
  55. 4.10 MannKind Corporation
  56. 4.10.1 MannKind Corporation Company Information
  57. 4.10.2 MannKind Corporation Business Overview
  58. 4.10.3 MannKind Corporation Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 MannKind Corporation Non-invasive Insulin Product Portfolio
  60. 4.10.5 MannKind Corporation Recent Developments
  61. 4.11 Janssen Pharmaceuticals
  62. 4.11.1 Janssen Pharmaceuticals Company Information
  63. 4.11.2 Janssen Pharmaceuticals Business Overview
  64. 4.11.3 Janssen Pharmaceuticals Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Janssen Pharmaceuticals Non-invasive Insulin Product Portfolio
  66. 4.11.5 Janssen Pharmaceuticals Recent Developments
  67. 4.12 Dance Biopharm
  68. 4.12.1 Dance Biopharm Company Information
  69. 4.12.2 Dance Biopharm Business Overview
  70. 4.12.3 Dance Biopharm Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Dance Biopharm Non-invasive Insulin Product Portfolio
  72. 4.12.5 Dance Biopharm Recent Developments
  73. 4.13 Bigfoot Biomedical
  74. 4.13.1 Bigfoot Biomedical Company Information
  75. 4.13.2 Bigfoot Biomedical Business Overview
  76. 4.13.3 Bigfoot Biomedical Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Bigfoot Biomedical Non-invasive Insulin Product Portfolio
  78. 4.13.5 Bigfoot Biomedical Recent Developments
  79. 4.14 Adocia
  80. 4.14.1 Adocia Company Information
  81. 4.14.2 Adocia Business Overview
  82. 4.14.3 Adocia Non-invasive Insulin Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Adocia Non-invasive Insulin Product Portfolio
  84. 4.14.5 Adocia Recent Developments
5 Global Non-invasive Insulin Market Scenario by Region
  1. 5.1 Global Non-invasive Insulin Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Non-invasive Insulin Sales by Region: 2021-2032
  3. 5.2.1 Global Non-invasive Insulin Sales by Region: 2021-2026
  4. 5.2.2 Global Non-invasive Insulin Sales by Region: 2027-2032
  5. 5.3 Global Non-invasive Insulin Revenue by Region: 2021-2032
  6. 5.3.1 Global Non-invasive Insulin Revenue by Region: 2021-2026
  7. 5.3.2 Global Non-invasive Insulin Revenue by Region: 2027-2032
  8. 5.4 North America Non-invasive Insulin Market Facts & Figures by Country
  9. 5.4.1 North America Non-invasive Insulin Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Non-invasive Insulin Sales by Country (2021-2032)
  11. 5.4.3 North America Non-invasive Insulin Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Non-invasive Insulin Market Facts & Figures by Country
  16. 5.5.1 Europe Non-invasive Insulin Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Non-invasive Insulin Sales by Country (2021-2032)
  18. 5.5.3 Europe Non-invasive Insulin Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Non-invasive Insulin Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Non-invasive Insulin Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Non-invasive Insulin Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Non-invasive Insulin Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Non-invasive Insulin Market Facts & Figures by Country
  41. 5.7.1 South America Non-invasive Insulin Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Non-invasive Insulin Sales by Country (2021-2032)
  43. 5.7.3 South America Non-invasive Insulin Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Non-invasive Insulin Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Non-invasive Insulin Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Non-invasive Insulin Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Non-invasive Insulin Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Non-invasive Insulin Sales by Type (2021-2032)
  2. 6.1.1 Global Non-invasive Insulin Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Non-invasive Insulin Sales Market Share by Type (2021-2032)
  4. 6.2 Global Non-invasive Insulin Revenue by Type (2021-2032)
  5. 6.2.1 Global Non-invasive Insulin Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Non-invasive Insulin Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Non-invasive Insulin Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Non-invasive Insulin Sales by Application (2021-2032)
  2. 7.1.1 Global Non-invasive Insulin Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Non-invasive Insulin Sales Market Share by Application (2021-2032)
  4. 7.2 Global Non-invasive Insulin Revenue by Application (2021-2032)
  5. 7.2.1 Global Non-invasive Insulin Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Non-invasive Insulin Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Non-invasive Insulin Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Non-invasive Insulin Value Chain Analysis
  2. 8.1.1 Non-invasive Insulin Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Non-invasive Insulin Production Mode & Process
  5. 8.2 Non-invasive Insulin Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Non-invasive Insulin Distributors
  8. 8.2.3 Non-invasive Insulin Customers
9 Global Non-invasive Insulin Analyzing Market Dynamics
  1. 9.1 Non-invasive Insulin Industry Trends
  2. 9.2 Non-invasive Insulin Industry Drivers
  3. 9.3 Non-invasive Insulin Industry Opportunities and Challenges
  4. 9.4 Non-invasive Insulin Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst